Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient

Table 4 Dapagliflozin in combination with metformin[24]

	Study 1			Study 2
Parameters	DAPA 5 ± MET	DAPA 5 ± PBO	MET ± PBO	DAPA 10 ± MET	DAPA 10 ± PBO	MET ± PBO
A1c at 24 wk (%)
Baseline (n)	9.21 (185)	9.14 (196)	9.14 (195)	9.1 (202)	9.03 (216)	9.03 (203)
A1c (%) at 24 wk (baseline change)	7.13 (-2.05)	7.96 (-1.19)	7.79 (-1.35)	7.1 (-1.98)	7.59 (-1.45)	7.6 (-1.44)
DAPA ± MET vs DAPA	-0.86 (-1.11, -0.62)			-0.53 (-0.74, -0.32)
P value	< 0.0001			< 0.0001
DAPA ± MET vs MET	-0.70 (-0.94, -0.45)			-0.43 (-0.75, -0.33)
P value	< 0.0001			< 0.0001
Patients with A1c < 7% at 24 wk
n (%)	96/185 (52.4%)	46/196 (22.5%)	68/195 (34.6%)	92/202 (46.6%)	69/216 (31.7%)	72/203 (35.2%)
DAPA ± MET vs DAPA	29.9	22.5		14.9
P value	< 0.0001			0.0012
DAPA ± MET vs MET	17.8			11.3
P value	< 0.0001			0.0165
Plasma glucose at 24 wk (mg/dL)
Baseline FPG (mg/dL)	193.14 (n = 192)	190.62 (n = 203)	196.56 (n = 200)	189.36 (n = 209)	197.28 (n = 216)	189.72 (n = 207)
FPG after 24 wk (baseline change)	132.3 (-61.02)	150.3 (-41.94)	161.1 (-33.48)	130.86 (-60.3)	147.6 (-46.44)	156.42 (-34.74)
DAPA ± MET vs DAPA	-19.08			-13.86
P value	< 0.0001			< 0.0001
DAPA ± MET vs MET	-27.54			-25.56
P value	< 0.0001			< 0.0001
Total body weight at 24 wk (kg)
Baseline weight (n)	84.24 (192)	86.20 (203)	85.75 (200)	88.56 (209)	88.53 (219)	87.24 (208)
Change from baseline	-2.66 (-3.14, -2.19)	-2.61 (-3.07, -2.15)	-1.29 (-1.76, -0.82)	-3.33 (-3.80, -2.86)	-2.73 (-3.19, -2.27)	-1.36 (-1.83, -0.89)

DAPA: Dapagliflozin; MET: Metformin; PBO: Placebo; FPG: Fasting plasma glucose; A1c: Hemoglobin A1c.